Carnitine palmitoyltransferase II deficiency
Nov. 24, 2024
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Mevalonate kinase deficiency
- Updated 10.17.2023
- Released 11.28.1994
- Expires For CME 10.17.2026
Mevalonate kinase deficiency
Introduction
Overview
Mevalonic aciduria and hyperimmunoglobulinemia D syndrome represent the extremes of a complex and continuous disease spectrum caused by deficiency of mevalonate kinase, the first committed enzyme of cholesterol and nonsterol isoprene biosynthesis. The author delineates the clinical entities of this multisystemic (inflammatory) disorder, the differential diagnosis, as well as therapeutic strategies. The diagnosis of mevalonic aciduria should be suspected in patients with mild dysmorphic features, progressive cerebellar ataxia, psychomotor retardation, failure to thrive, hepatosplenomegaly, liver failure, and, especially, recurrent febrile episodes. Uveitis, retinitis pigmentosa, cataracts, inflammatory bowel disease, and (cardio-) myopathy may develop in childhood and adolescence.
Mevalonic aciduria and hyperimmunoglobulinemia D syndrome are both characterized by recurrent, episodic, high-grade fever with lymphadenopathy, arthralgia, gastrointestinal problems, skin rashes, and oral or genital ulcers. Rarely, affected individuals with hyperimmunoglobulinemia D syndrome develop neonatal-onset chronic hepatitis or colitis, erosive polyarthritis or Sjögren syndrome, amyloidosis, renal angiomyolipoma, or neurologic symptoms only. Shortage of nonsterol isoprenes as well as activation of the pyrin inflammasome and overproduction of the cytokine interleukin-1 beta (IL-β) are central to the pathophysiology. In most patients, drugs targeting IL-β ameliorate or abort symptoms.
Key points
|
• Mevalonic aciduria, hyperimmunoglobulinemia D, and periodic fever syndrome are allelic diseases caused by monogenic defects of mevalonate kinase, resulting in a continuous spectrum of clinical symptoms. “Mevalonate kinase deficiency” is the common term for these conditions. | |
|
• Mevalonic aciduria is a severe multisystemic disease. Cardinal manifestations include dysmorphic features, mild to severe psychomotor retardation, failure to thrive, hypotonia, progressive proximal myopathy, hepatopathy, and severe recurrent inflammatory crises (musculoskeletal symptoms, fever, vomiting, and diarrhea). | |
|
• Hyperimmunoglobulinemia D syndrome is an early-onset periodic fever syndrome within a group of hereditary periodic fever syndromes. It is caused by increased plasma levels of cytokines, leading to an array of inflammatory symptoms and often long-term multisystem disease. | |
|
• Two criteria are pathognomonic for mevalonate kinase deficiency: onset of disease before 5 years of age or fever attacks combined with arthralgia lasting less than 14 days. If these criteria are not met, metabolic or molecular investigations for mevalonate kinase deficiency are mostly unwarranted. | |
|
• Individual patients can present with a monosymptomatic disease such as neonatal-onset chronic hepatitis, colitis or interstitial lung disease, ataxia, or retinitis pigmentosa. | |
|
• Disseminated superficial actinic porokeratosis could be linked to dominant mutations in mevalonate kinase. |
Historical note and terminology
Mevalonic aciduria, hyperimmunoglobulinemia D syndrome, and periodic fever syndrome are allelic recessive diseases with a continuous spectrum of clinical symptoms and severity caused by monogenic defects of mevalonate kinase, making “mevalonate kinase deficiency” the common and preferable term for these conditions. The defective enzyme is located proximally in the biosynthesis of cholesterol and nonsterol isoprenes. Although cholesterol metabolism has been the focus of intense research for decades and about 80% of cholesterol is derived by endogenous synthesis, mevalonic aciduria due to mevalonate kinase deficiency was only recognized in 1986 as the first inherited defect in cholesterol biosynthesis (27).
Mevalonic aciduria remains a rare disorder with slightly over 40 patients reported (03; 09; 19; 26; 38; 23; 24; 12; 59; 46; 48; 54; 51; 02; 08; 50; 44; 13; 45; 06).
Over 400 patients are known to suffer from hyperimmunoglobulinemia D syndrome, an autoinflammatory disorder, which was found to be allelic to mevalonic aciduria in 1999 (30; 62; 02; 56; 57). The relatively high prevalence in North European countries has been suggested to result from a selective advantage of carriers for lower cholesterol levels in countries where the diet contains high amounts of saturated animal fats rich in cholesterol (63).
Disseminated superficial actinic porokeratosis could be linked to dominant mutations in in mevalonate kinase (66; 35).
Clinical manifestations
Presentation and course
Mevalonic aciduria shows considerable clinical heterogeneity, including an almost asymptomatic course (06). Stillbirths with skeletal malformations have been observed in affected families, possibly a result of the same genetic defect. Severely affected patients can present prenatally with hydrops fetalis (44) and at birth with congenital malformations and dysmorphic features such as microcephaly, dolichocephaly, wide irregular fontanelles, low-set and posteriorly rotated ears, down-slanted palpebral fissures, blue sclerae, and central cataracts (44). Signs of perinatal infection, together with chronic liver disease (52), interstitial lung disease (45), or neonatal-onset refractory colitis and recurrent rectal abscesses (13) may be mistaken for congenital infection, eg, cytomegalovirus infection. Cholestatic liver disease or neonatal-onset chronic hepatitis can progress to liver failure (08).
Cardinal manifestations include recurrent crises from infancy (high fever, vomiting, diarrhea, arthralgia, and mucocutaneous symptoms, such as aphthous stomatitis, pharyngitis, and skin rashes), failure to thrive, mild to severe psychomotor retardation, hypotonia, and (cardio-)myopathy. The latter can be slowly progressive and affects predominantly axial and proximal muscles. Patients may die of recurrent septicemia, macrophage activation syndrome, or multiorgan failure. Sometimes hematologic abnormalities predominate with normocytic hypoplastic anemia, leukocytosis, thrombocytopenia, and abnormal blood cell forms (23). These abnormalities may lead to the (mis)diagnoses of myelodysplastic syndromes or dyserythropoietic anemia (51; 02). Short stature, ataxia due to progressive cerebellar atrophy and ocular involvement with cataracts and retinal dystrophy become predominant findings after preschool age and can be major manifestations in later onset cases (26; 38; 46; 54; 50; 06).
In hyperimmunoglobulinemia D syndrome, recurrent febrile attacks are similar in frequency and severity to those in patients with mevalonic aciduria. The episodes last from 1 to 10 days with a median duration of 4 days and 12 to 30 episodes per year. Abdominal pain, arthralgia, headache, aphthae, and rashes dominate the clinical course (62; 02; 17; 07; 57; 65). Occasionally, patients present with oral and vaginal aphthous ulcers. The median age of first attack is 4 months (range, 0 to 240 months), with a median period of 8 to 10 years from onset of disease to diagnosis (65). Patients rarely remain asymptomatic throughout childhood and adolescence (57). The majority of patients have increased serum concentrations of IgD; however, 20% to 30% of patients with mevalonate kinase mutations and characteristic symptoms have normal serum IgD concentrations (12; 57). The frequency of attacks often decreases with the patient’s age and may subside in adolescence. However, 50% of adult patients still suffer from six or more attacks per year, life-threatening infections, and other autoimmune features, such as erosive polyarthritis, Sjögren syndrome, nummular keratopathy, and tumors. Renal amyloidosis has been observed as a long-term complication in about 4% (57). Gastrointestinal symptoms are very frequent during intercurrent crises but can also predominate and become continuous up to severe and early-onset colitis, requiring parental nutrition and inflammatory bowel disease-like intestinal inflammation, early onset ulcerative colitis, or proctitis (37; 57). Repeated aseptic peritonitis, jejunal obstruction, GI bleeding, ulcers, and intestinal perforation have been reported (43; 57). Most patients with hyperimmunoglobulinemia D syndrome display neither malformations nor neurologic abnormalities. However, a subgroup of adult patients develops neurologic signs or symptoms of various degrees, such as intellectual disability, ataxia, ocular symptoms, and epilepsy, reflecting a continuous spectrum between mevalonic aciduria and hyperimmunoglobulinemia D syndrome (59; 54; 02).
Most troublesome are frequent crises (26; 36; 02; 08; 50; 57; 65; 33; 06). These are characterized by high fever (frequently exceeding 40°C), vomiting, and diarrhea and are accompanied by abdominal pain, arthralgia, headache, subcutaneous edema, aphthous ulcers, and morbilliform rashes in some patients.
These episodes appear to be noninfectious but can be triggered by minor intercurrent illnesses, vaccinations, or stress. Some patients develop uveitis, which worsens during crises, and others develop progressive myopathies. In childhood, episodes occur as often as 25 times per year, lasting 4 to 7 days on average. Laboratory investigations reveal elevated acute phase reactants (erythrocyte sedimentation rate, C-reactive protein, leukocytosis) and elevated immunoglobulins, including IgA, IgE, and, especially, IgD. The severity of the attacks does not correlate with the level of IgD in serum, and attacks may occur in small children before IgD concentrations become elevated. In the more severely affected patients, anemia, elevations of creatine kinase, and transaminases are present and may worsen during crises. Over years, the severity and the frequency of these attacks often decline and may eventually subside in adolescence, but they mostly persist for life (06). Very few patients never develop immunological crises and may present with mono- or oligosymptomatic late-onset nonsyndromic retinitis pigmentosa (53), sacroiliitis (11), inflammatory bowel disease, liver or cardiorespiratory disease, amyloid A amyloidosis, ataxia, or developmental delay only.
In an array of papers, heterozygous mutations in mevalonate kinase were identified as the cause of disseminated superficial actinic porokeratosis, an autosomal dominant skin disease localized to the skin and characterized by epidermal keratinization (66; 35).
Prognosis and complications
The prognosis for patients with mevalonic aciduria is severe but variable (26; 46; 50; 65; 06). A significant proportion of patients die within the first years of life. Beyond school age, the clinical course appears to be relatively stable with borderline intellectual disability, short stature, cerebellar ataxia, and muscular hypotonia in adolescence. Retinal dystrophy may become an important long-term manifestation of the disease. The dystrophic retinal process does not necessarily manifest itself as retinitis pigmentosa-like bone spicule pigmentations of the fundus. Cataracts and optic atrophy may be accompanying signs of retinal dystrophy. Therefore, the diagnostic evaluation and follow-up care should include ocular electrophysiology.
Hyperimmunoglobulinemia D syndrome has generally been considered to be a relatively benign condition. However, general health and social functioning were found to be significantly impaired, and long-term complications such as inflammatory bowel disease, erosive polyarthritis, Sjögren syndrome, and other chronic conditions are increasingly recognized (02; 57). Even with “only” inflammatory symptoms, general health perception and social functioning were found to be significantly impaired in patients. The functional impairments can have an adverse impact on quality of life, educational achievements, and employment status (62; 17). Furthermore, life expectancy may be reduced in some patients due to severe infections or the development of renal amyloidosis.
Biological basis
Etiology and pathogenesis
Mevalonic aciduria and hyperimmunoglobulinemia D syndrome are caused by a recessively inherited deficiency of mevalonate kinase (E.C. 2.7.1.36; ATP:(R)-mevalonate 5-phosphotransferase; McKusick 251170). The gene encoding mevalonate kinase (MVK) is located on chromosome 12q24 (20). Currently, more than 300 mutations have been reported on Infevers, an online database for autoinflammatory mutations. In mevalonic aciduria, mutations often cluster in the C-terminal region of the protein (24; 06). About 80% of patients with hyperimmunoglobulinemia D syndrome harbor the missense p.V337I mutation, a founder mutation in the Netherlands (02). This mutation primarily affects maturation (folding) of the protein, resulting in a temperature-sensitive expression of mevalonate kinase in vivo (30). In patients with hyperimmunoglobulinemia D syndrome, residual activity of mevalonate kinase of 5% to 15% may be demonstrable, whereas activity is absent in mevalonic aciduria patients (26).
Mevalonic acid is the product of the reaction catalyzed by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key regulatory site in the de novo synthesis of sterols and nonsterol isoprenes. In animals, the major product of mevalonate metabolism is cholesterol, some of which is converted to steroid hormones, bile acids, and vitamin D. Mevalonic acid is also converted into other products, including: (1) dolichols, which act as carriers in the assembly of carbohydrate chains of glycoproteins; (2) ubiquinones, which participate in electron transport and, consequently, mitochondrial function; (3) isopentenylated transfer RNAs, which are important for protein synthesis; and (4) geranylylated and farnesylated proteins (21). The latter are involved in intracellular signal transduction, growth control, and the cell cycle, including the proto-oncogene ras. Feedback inhibition from some of the mevalonate pathway substrates, specifically geranylgeranyl pyrophosphate and farnesyl pyrophosphate, proved nonsterol isoprenoids to have a key role in the regulation of mevalonate kinase. The impairment of geranylgeranylation and secondary disturbed geranylgeranylation of small guanosine triphosphatases (GTPases), which are linked to interleukin-1 activation, appear to be central for the inflammatory disease manifestations (61). In vivo loss of small GTPases, including RhoA or K-Ras, could be documented in affected patients, resulting in activation of the pyrin inflammasome and IL-1β secretion (41; 33). In addition, impaired isoprenylation results in impaired mitochondrial function as well as autophagy (60) and, consequently, increased IL-1 β secretion, activation of caspase-1 and caspase-3-related apoptosis, and, partly, caspase-1-associated pyroptosis, resulting in inflammasome activation and inflammatory reaction with fever.
In contrast to most inborn errors of metabolism, mevalonate kinase deficiency is a defect of a biosynthetic pathway. Symptoms are caused by a deficiency of end products and not by toxicity of the accumulating intermediate mevalonic acid. Intervention with lovastatin, an HMG-CoA reductase inhibitor, was attempted in two patients with mevalonic aciduria to ascertain if clinical manifestations might be the result of mevalonate toxicity (26). Doses of 0.3 to 0.6 mg/kg per day for more than 2 weeks resulted in severe critical clinical decompensation manifesting as elevated body temperature, acute myopathy, highly elevated creatine kinase, and worsened ataxia, diarrhea, and vomiting. After cessation of lovastatin therapy, clinical and biochemical changes slowly reversed. In 2019, Frey and colleagues confirmed in control blood mononuclear cells that inhibition of the mevalonate pathway with lovastatin resulted in increased response of IL-6, IL-12p40, and IFN-g mRNA following stimulation (16). This effect was abolished by adding mevalonate to the assay. Different from other autoinflammatory disorders, mevalonate kinase deficiency is a multicytokine disease with increased plasma levels of cytokines.
Despite lack of residual mevalonate kinase activity in cultured cells from affected patients, plasma levels of cholesterol are normal to near normal (partially related to more efficient uptake from the diet), as are the serum levels of lipoprotein, apolipoproteins, steroid hormones, and primary bile acids (26). In cultured skin fibroblasts from affected patients, the activities of HMG-CoA reductase and the levels of LDL receptors are significantly upregulated (29). HMG-CoA reductase and the LDL receptor are the key regulatory sites in the cholesterol pathway (21). Apparently, upregulated activities are compensatory responses in mevalonate kinase deficiency, ensuring (almost) sufficient production of mevalonic acid and thereby almost normal functioning of the pathway. Biallelic hypomorphic variants in HMG-CoA reductase could be identified in 15 individuals in six families, all from whole exome sequencing data of patients with limb-girdle muscular dystrophy (40; 64). In addition to elevated CK levels, plasma mevalonate was found to be reduced, when determined. In one severely affected patient, mevalonolactone was administered orally with 16 mg/kg bw up to three times a week. Impressive subjective as well as objective improvements occurred in all affected muscle groups, including the respiratory muscles, from 3 weeks of treatment. This resulted in significant lasting improvement in independence and daily activities. Bridging the pathophysiological link, the phenotype in some patients was reminiscent of statin-induced myopathy. Finally, in very rare instances, patients treated with statins can develop an autoimmune myopathy caused by antibodies against HMG-CoA reductase, resulting in limb-girdle muscular dystrophy (39).
Ubiquinone biosynthesis in cultured patient fibroblasts is decreased, consistent with decreased plasma levels of ubiquinone-10 in plasma from patients, whereas cholesterol biosynthesis in fibroblasts is normal (31; 29). These findings suggested that geranyl- and farnesyl-pyrophosphate, important intermediates at the branch-point between sterol and isoprenoid biosynthesis, are shuttled toward cholesterol synthesis at the expense of isoprene biosynthesis. Mitochondrial dysfunction due to reduced ubiquinone could be the link between neuroinflammation and neuronal degeneration.
The pathophysiological role of nonsterol isoprenes is further strengthened by the identification of biallelic variants in the GGPSI (MIM: 606982) gene as a “new” cause of congenital muscular dystrophy with sensorineural hearing loss (34). Elevation of IgD levels as well as elevated urinary LTE4 excretion appear to be secondary phenomena of the stimulation of the immune system (15). Oligosymptomatic disease courses, the fact that neurologic and inflammatory symptoms may occur at different ages, and that affected individuals with mevalonate kinase deficiency may have normal levels of IgD or no characteristic crises, suggest that a number of different pathogenetic mechanisms or constellations are responsible for the different clinical manifestations. Impaired prenylation of many proteins synthesized specifically in the retina was delineated as the cause of degeneration of photoreceptors, the retinal pigment epithelium, and the choroid in mevalonate kinase deficiency (49).
Epidemiology
Patients with mevalonic aciduria and hyperimmunoglobulinemia D syndrome and periodic fever syndrome have been identified in families of differing nationalities, although a high proportion of patients are from Northern Europe, including Germany, the Netherlands, and Czechoslovakia (26; 62; 02; 65; 06). Whether this is suggestive of a founder effect, a result of more accurate investigations for mevalonate kinase deficiency in European centers, or the result of a selective advantage of carriers for lower cholesterol levels in countries where the diet contains high amounts of saturated animal fats rich in cholesterol (63) is not known.
Prevention
Only the mating of heterozygotes for mevalonate kinase deficiency can result in an affected child, with each pregnancy having a 1 in 4 chance of producing an affected fetus. Genetic counseling for a family with a previously documented child is recommended. Mevalonic acid may be measured accurately in amniotic fluid by use of an isotope dilution gas chromatography/mass spectrometry assay method employing deuterium-labeled mevalonic acid as internal standard (28). Mevalonate kinase activity can be measured in cultured amniocytes and biopsied chorionic villus tissue (27; 25), and molecular diagnosis can be performed in informative families.
Genetics are different in disseminated superficial actinic porokeratosis; both dominant germline and somatic variants have been described in the mevalonate kinase gene.
Differential diagnosis
Although patients with mevalonate kinase deficiency have a recognizable phenotype of serious clinical manifestations, many will remain undiagnosed for years, on average 8 to 10 years (26; 02; 06). This is even more the case in patients displaying mono- or oligosymptomatic manifestations such as neonatal-onset hepatitis or colitis, ataxia, or retinitis pigmentosa. In a survey of hyperimmunoglobulinemia D syndrome, the median period from onset of disease to diagnosis was 9.9 years (62). Metabolic acidosis, lactic acidemia, and hyperammonemia, the usual concomitants of organic acid disorders, are conspicuously absent.
In more severely affected patients with mevalonic aciduria, the constellation of early-onset failure to thrive, congenital malformations, developmental retardation, hepatosplenomegaly, lymphadenopathy, and anemia might suggest chromosomal aberrations or congenital infections. Sometimes hematological abnormalities predominate with normocytic hypoplastic anemia, leukocytosis, thrombocytopenia, and abnormal blood cell forms (23), leading to misdiagnoses of myelodysplastic syndromes or dyserythropoietic anemia (51). Moderately affected patients may be classified among those with psychomotor retardation, myopathy, specifically limb-girdle muscular dystrophy, and ataxia. Recurrent crises with fever, diarrhea, arthralgia, and mucocutaneous manifestations might suggest infectious or autoimmune disease (26). The development of uveitis in some patients parallels that seen in juvenile rheumatoid arthritis (46).
If developmental delay and neurologic symptoms are not prominent, the differential diagnosis is likely to focus within the group of systemic autoinflammatory disorders. This group consists of other inherited syndromes: familial Mediterranean fever; TNF receptor-associated periodic syndrome; cryopyrin-associated periodic syndrome; familial cold autoinflammatory syndrome/Muckle-Wells syndrome/chronic infantile neurologic cutaneous and articular syndrome; periodic fever and aphthous ulcers, pharyngitis, and adenitis (PFAPA syndrome); pyogenic arthritis pyoderma acne syndrome (PAPA syndrome); NLRP12-associated periodic syndrome and DIRA (interleukin-1 receptor antagonist deficiency) syndrome.
Diagnostic workup
The major diagnostic criterion for mevalonic aciduria is persistently, grossly elevated mevalonic acid in urine, plasma, and CSF (28; 26). Hyperimmunoglobulinemia D syndrome is often suggested by the demonstration of elevated IgD, elevated lgA in 80% of patients, and can be confirmed by elevated mevalonic acid in urine. However, IgD is often normal in children younger than 3 years of age and in 20% to 30% of older individuals (30; 57). Patients with mevalonic aciduria excrete about 500 to 56,200 mmol mevalonic acid/mol creatinine in urine compared to 0.09 to 0.43 mmol/mol creatinine in controls (26). In milder affected patients and especially in hyperimmunoglobulinemia D syndrome, significant elevations may only be found during febrile crises with only slight elevations between attacks, or they may even remain normal (57). The sensitivity of organic acid analysis is inadequate to recognize these slight elevations because of multiple secondary product formation during gas chromatography and mass spectrometry analysis (28). Accurate quantification of mevalonic acid is achieved only by using an isotope dilution gas chromatography/mass spectrometry assay method, employing deuterium-labeled mevalonic acid as internal standard (28). Therefore, a specific suspicion should be followed by a sensitive measurement of mevalonic acid by stable isotope dilution analysis. Sensitivity is 92% and specificity 90% (32). The diagnosis should be confirmed by mutation analysis or assay of mevalonate kinase in white blood cells or cultured fibroblasts (25), but again, one patient with proven pathogenic mutations and elevated mevalonate acid excretion has been identified, whose enzyme activity was reportedly entirely normal (61). Carrier detection is also possible by enzymatic essay, although the results are sometimes equivocal, or by DNA analysis, if mutations have been found in the index patient (24).
Management
Despite the rarity of the disorder, therapeutic regimens for mevalonic aciduria have been at least partially studied (33). Dietary supplementation of cholesterol may reduce frequency and severity of febrile attacks in some mildly affected patients but has compromised more severely affected patients (26). Long-term administration of ubiquinone-50 together with vitamin C and E appears to further stabilize the clinical course and improve somatic and psychomotor development. The rationale is to correct ubiquinone-50 deficiency and to increase free radical scavengers (46). Intervention with paracetamol/NSAIDs plus corticosteroids (prednisone 2 mg /kg per day) is beneficial in about a third of patients during clinical crises, often with resolution of the crises within 24 hours. Treatment with the IL-1 receptor antagonist canakinumab for IL-1 blockade shows the best effects (17; 37; 33) and has been approved by the European Medicines Agency and U.S. Food and Drug Administration for the treatment of mevalonate kinase deficiency. In addition, an on-demand use of anakinra can significantly shorten relapses (04). In individual patients with unsatisfactory response, tocilizumab, a humanized monoclonal antibody targeting the IL-6 receptor, has been successful (47). In 2007, Neven and colleagues reported a positive response to allogenic stem cell transplantation in a boy with mevalonic aciduria and severe, life-threatening inflammatory attacks that could not be controlled (42). This report has been supported by similar successes in a few patients (08; 18) and even by haploidentical alpha/beta T-cell and B-cell depleted stem cell transplantation, with a low risk of acute and chronic graft-versus-host disease or infective complications (14). In one girl, improvement of cerebral myelination was demonstrated on MRI after allogenic stem cell transplantation. This patient also showed resolution of spastic diplegia following additional liver transplantation. Stem cell transplantation offers an important therapeutic option for severe mevalonic aciduria, including its neurologic features. However, there is a risk of relapse; therefore, this procedure is not a fully curative option (55).
Treatment of hyperimmunoglobulinemia D syndrome is also difficult and often supportive. Various standard antiinflammatory drugs including colchicine, NSAIDs, steroids, and thalidomide have failed to suppress the attacks. About a quarter of patients respond favorably to nonsteroidal anti-inflammatory drugs (NSAIDs) or high-dose prednisone (17; 33). Anti-TNF treatment showed a positive response in a few patients (10; 58). IL-1 blockade by the receptor antagonists anakinra or canakinumab have emerged as the treatment of choice, with more patients responding to anakinra (90%) than to etanercept (65%). Anakinra is rapidly eliminated with a serum half-time of 4 to 6 hours, whereas the half-time of canakinumab is 22 to 25 days, meaning that it only needs to be administered once every 6 to 8 weeks (05; 62; 17; 58; 22) with better results (01). Side effects of anakinra have included pain at the injection site (04) and neutropenia, and higher doses may be associated with infectious complications such as bacterial pneumonia (17) and herpes zoster infection (07). Patient initiated on-demand treatment starting at the prodromal stage of the attack with the IL-1 receptor antagonist anakinra was shown to decrease the duration and severity of fever attacks in most patients (04; 17) and is an alternative to continuous therapy. Again, the therapeutic effect is possibly better with canakinumab (17; 58; 22). Only canakinumab has been approved by the European Medicines Agency and U.S. Food and Drug Administration for the treatment of mevalonate kinase deficiency. Unfortunately, the costs of canakinumab are about 7 to 10 times those of anakinra.
Long-term follow-up should include regular general physical examination, monitoring growth and development of children, ophthalmological examination for retinitis pigmentosa and cataracts, neurologic examination, blood count, and measurement of inflammatory parameters, such as C-reactive protein and serum amyloid A, and muscle and liver enzymes. Urine analysis should be performed for renal complications such as glomerulonephritis and renal angiomyolipoma.
Special considerations
Pregnancy
Prenatal diagnosis of mevalonic aciduria is possible via molecular investigations in informative families. In at-risk families, mevalonic acid can be measured accurately in amniotic fluid by an isotope-dilution gas chromatography and mass spectrometry method. Determination of mevalonate kinase activity in cultured amniocytes and biopsied chorionic villus is also possible (27; 28; 25; 38). In affected pregnancies, elevated levels of mevalonic acid have been detected in maternal urine (27; 28; 38). Significant elevations of mevalonic acid were detected in autopsied tissues from an affected fetus, including lymph nodes, adrenals, ovaries, spleen, liver, and brain (28).
Hyperimmunoglobulinemia D syndrome is usually not considered appropriate for prenatal diagnosis.
Media
References
- 01
- Arostegui JI, Anton J, Calvo I, et al. Open-label, phase II study to assess the efficacy and safety of canakinumab treatment in active hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheumatol 2017;69(8):1679-88. PMID 28482144
- 02
- Bader-Meunier B, Florkin B, Sibilia J, et al. Mevalonate kinase deficiency: a survey of 50 patients. Pediatrics 2011;128(1):e152-9. PMID 21708801
- 03
- Berger R, Smit GP, Schierbeek H, Bijsterveld K, le Coultre R. Mevalonic aciduria: an inborn error of cholesterol biosynthesis. Clin Chim Acta 1985;152(1-2):219-22. PMID 4053401
- 04
- Bodar EJ, Kuijk LM, Drenth JP, et al. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis 2011;70(12):2155-8. PMID 21859689
- 05
- Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 2005;63:260-4. PMID 16093577
- 06
- Brennenstuhl H, Nashawi M, Schröter J, et al. Phenotypic diversity, disease progression, and pathogenicity of MVK missense variants in mevalonic aiduria. J Inherit Metab Dis 2021;44(5):1272-87. PMID 34145613
- 07
- Campanilho-Marques R, Brogan PA. Mevalonate kinase deficiency in two sisters with therapeutic response to anakinra: case report and review of the literature. Clin Rheumatol 2014;33(11):1681-4. PMID 24531849
- 08
- Chaudhury S, Hormaza L, Mohammad S, et al. Liver transplantation followed by allogeneic hematopoietic stem cell transplantation for atypical mevalonic aciduria. Am J Transplant 2012;12(6):1627-31. PMID 22405037
- 09
- de Klerk JB, Duran M, Dorland L, Brouwers HA, Bruinvis L, Ketting D. A patient with mevalonic aciduria presenting with hepatosplenomegaly, congenital anaemia, thrombocytopenia and leukocytosis. J Inherit Metab Dis 1988;11 Suppl 2:233-6. PMID 3141709
- 10
- Demirkaya E, Caglar MK, Waterham HR, Topaloglu R, Ozen S. A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 2007;26(10):1757-9. PMID 17171314
- 11
- Di Gangi M, Amato G, Converso G, et al. Long-term efficacy of adalimumab in hyperimmunoglobulin D and periodic fever syndrome. Isr Med Assoc J 2014;16(10):605-7. PMID 25438442
- 12
- Di Rocco M, Caruso U, Waterham HR, Picco P, Loy A, Wanders RJ. Mevalonate kinase deficiency in a child with periodic fever and without hyperimmunoglobulinemia D. J Inherit Metab Dis 2001;24(3):411-2. PMID 11486909
- 13
- Dunn K, Pasternak B, Kelsen JR, et al. Mevalonate kinase deficiency presenting as recurrent rectal abscesses and perianal fistulae. Ann Allergy Asthma Immunol 2018;120(2):214-5. PMID 29290516
- 14
- Faraci M, Giardino S, Podesta M, et al. Haploidentical alpha/beta T-cell and B-cell depleted stem cell transplantation in severe mevalonate kinase deficiency. Rheumatology (Oxford) 2021;60(10):4850-4. PMID 33410495
- 15
- Frenkel J, Willemsen MA, Weemaes CM, Dorland L, Mayatepek E. Increased urinary leukotriene E(4) during febrile attacks in the hyperimmunoglobulinemia D and periodic fever syndrome. Arch Dis Child 2001;85(2):158-9. PMID 11466192
- 16
- Frey T, Swade K, Zwecker L, et al. Monocyte production of IFN- γ is interleukin-12 dependent in a model of mevalonate kinase deficiency. J Interferon Cytokine Res 2019;39(6):364-74. PMID 31013450
- 17
- Galeotti C, Meinzer U, Quartier P, et al. Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency. Rheumatology (Oxford) 2012;51(10):1855-9. PMID 22740624
- 18
- Giardino S, Lanino E, Morreale G, et al. Long-term outcome of a successful cord blood stem cell transplant in mevalonate kinase deficiency. Pediatrics 2015;135(1):e211-5. PMID 25535259
- 19
- Gibson KM, Hoffmann GF, Sweetman L, Buckingham B. Mevalonate kinase deficiency in a dizygotic twin with mild mevalonic aciduria. J Inherit Metab Dis 1997a;20(3):391-4. PMID 9266363
- 20
- Gibson KM, Hoffmann GF, Tanaka RD, Bishop RW, Chambliss KL. Mevalonate kinase map position 12q24. Chromosome Res 1997b;5(2):150. PMID 9146921
- 21
- Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30. PMID 1967820
- 22
- Hansmann S, Lainka E, Horneff G, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online 2020;18(1):17. PMID 32066461
- 23
- Hinson DD, Rogers ZR, Hoffmann GF, et al. Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. Am J Med Genet 1998;78(5):408-12. PMID 9714005
- 24
- Hinson DD, Ross RM, Krisans S, et al. Identification of a mutation cluster in mevalonate kinase deficiency, including a new mutation in a patient of Mennonite ancestry. Am J Hum Genet 1999;65(2):327-35. PMID 10417275
- 25
- Hoffmann GF, Brendel SU, Scharfschwerdt SR, Shin YS, Speidel IM, Gibson KM. Mevalonate kinase assay using DEAE-cellulose column chromatography and complementation analysis in mevalonic aciduria. J Inherit Metab Dis 1992;15:738-46. PMID 1331607
- 26
- Hoffmann GF, Charpentier C, Mayatepek E, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics 1993;91:915-21.** PMID 8386351
- 27
- Hoffmann GF, Gibson KM, Brandt IK, Bader PI, Wappner RS, Sweetman L. Mevalonic aciduria—an inborn error of cholesterol and nonsterol isoprene biosynthesis. N Engl J Med 1986;314(25):1610-4. PMID 3012338
- 28
- Hoffmann GF, Sweetman L, Bremer HJ, et al. Facts and artefacts in mevalonic aciduria: development of a stable isotope dilution GCMS assay for mevalonic acid and its application to physiological fluids, tissue samples, prenatal diagnosis and carrier detection. Clin Chim Acta 1991;198:209-27. PMID 1653652
- 29
- Hoffmann GF, Wiesmann UN, Brendel S, Keller RK, Gibson KM. Regulatory adaptation of isoprenoid biosynthesis and the LDL receptor pathway in fibroblasts from patients with mevalonate kinase deficiency. Pediatr Res 1997;41(4 Pt 1):541-6. PMID 9098857
- 30
- Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinemia D and periodic fever syndrome. Nat Genet 1999;22(2):175-7. PMID 10369261
- 31
- Hubner C, Hoffmann GF, Charpentier C, et al. Decreased plasma ubiquinone-10 concentration in patients with mevalonate kinase deficiency. Pediatr Res 1993;34(2):129-33. PMID 8233712
- 32
- Jeyaratnam J, Ter Haar NM, de Sain-van der Velden MG, Waterham HR, van Gijn ME, Frenkel J. Diagnostic value of urinary mevalonic acid excretion in patients with a clinical suspicion of mevalonate kinase deficiency (MKD). JIMD Rep 2016;27:33-8. PMID 26409462
- 33
- Jeyaratnam J, Frenkel J. Management of mevalonate kinase deficiency: a pediatric perspective. Front Immunol 2020;11:1150. PMID 32582214
- 34
- Kaiyrzhanov R, Perry L, Rocca C, et al. GGPS1-associated muscular dystrophy with and without hearing loss. Ann Clin Transl Neurol 2022;9(9):1465-74. PMID 35869884
- 35
- Kubo A, Sasaki T, Suzuki H, et al. Clonal expansion of second-hit cells with somatic recombinations or C>T transitions form porokeratosis in MVD or MVK mutant heterozygotes. J Investig Dermatol 2019;139:2458-66.e9. PMID 31207227
- 36
- Kuijk LM, Beekman JM, Koster J, Waterham HR, Frenkel J, Coffer PJ. HMG-CoA reductase inhibition induces IL-1β release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008;112(9):3563-73. PMID 18684863
- 37
- Levy M, Arion A, Berrebi D, et al. Severe early-onset colitis revealing mevalonate kinase deficiency. Pediatrics 2013;132(3);e779-83. PMID 23979089
- 38
- Mancini J, Philip N, Chabrol B, Divry P, Rolland MO, Pinsard N. Mevalonic aciduria in three siblings: a new recognizable metabolic encephalopathy. Pediatr Neurol 1993;9:243-6. PMID 8352861
- 39
- Mohassel P, Landon-Cardinal O, Foley AR, et al. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm 2018;6(1):e523. PMID 30588482
- 40
- Morales-Rosado J, Schwab TL, Macklin-Mantia SK, et al. Bi-allelic variants in HMGCR cause an autosomal-recessive progressive limb-girdle muscular dystrophy. Am J Hum Genet 2023;110(6):989-97. PMID 37167966
- 41
- Munoz MA, Jurczyluk J, Mehr SM, et al. Defective protein prenylation is a diagnostic biomarker of mevalonate kinase deficiency. J Allergy Clin Immunol 2017;140(3):873-5. PMID 28501347
- 42
- Neven B, Valayannopoulos V, Quartier P, et al. Allogeneic bone marrow transplantation in mevalonic aciduria. N Engl J Med 2007;356(26):2700-3. PMID 17596604
- 43
- Nimubona L, Laloum D, Rolland MO, Read MH, Guillois B, Duhamel JF. An intestinal obstruction in an eight-month-old child suffering from mevalonic aciduria. Acta Paediatr 2002;91(6):714-6. PMID 12162608
- 44
- Peciuliene S, Burnyte B, Gudaitiene R, et al. Perinatal manifestation of mevalonate kinase deficiency and efficacy of anakinra. Pediatr Rheumatol Online 2016;14(1):19. PMID 27012807
- 45
- Pietrasanta C, Minoia F, Torreggiani S, et al. When neonatal inflammation does not mean infection: an early-onset mevalonate kinase deficiency with interstitial lung disease. Clin Immunol 2019;205:25-8. PMID 31096039
- 46
- Prietsch V, Mayatepek E, Krastel H, et al. Mevalonate kinase deficiency: enlarging the clinical and biochemical spectrum. Pediatrics 2003;111(2):258-61. PMID 12563048
- 47
- Rafiq NK, Lachmann H, Joensen F, Herlin T, Brogan PA. Tocilizumab for the treatment of mevalonate kinase deficiency. Case Rep Pediatr 2018;2018:3514645. PMID 30225156
- 48
- Raupp P, Varady E, Duran M, Wanders RJA, Waterham HR, Houten SM. Novel genotype of mevalonic aciduria with fatalities in premature siblings. Arch Dis Child Fetal Neonatal Ed 2004;89:F90-1. PMID 14711867
- 49
- Roosing S, Collin RW, den Hollander AI, Cremers FP, Siemiatkowska AM. Prenylation defects in inherited retinal diseases. J Med Genet 2014;51(3):143-51. PMID 24401286
- 50
- Ruiz Gomez A, Couce ML, Garcia-Villoria J, et al. Clinical, genetic, and therapeutic diversity in two patients with severe mevalonate kinase deficiency. Pediatrics 2012;129(2):e535-9. PMID 22271696
- 51
- Samkari A, Borzutzky A, Fermo E, Treaba DO, Dedeoglu F, Altura RA. A novel missense mutation in MVK associated with MK deficiency and dyserythropoietic anemia. Pediatrics 2010;125(4):e964-8. PMID 20194276
- 52
- Satekge TM, Kiabilua O, Terblanche AJ, Bida M, Pillay TS. Mevalonate kinase deficiency masked by cytomegalovirus infection and obscure liver disease. Clin Chim Acta 2019;498:122-5. PMID 31430439
- 53
- Siemiatkowska AM, van den Born LI, van Hagen PM, et al. Mutations in the mevalonate kinase (MVK) gene cause nonsyndromic retinitis pigmentosa. Ophthalmology 2013;120(12):2697-705. PMID 24084495
- 54
- Simon A, Kremer HP, Wevers RA, et al. Mevalonate kinase deficiency: Evidence for a phenotypic continuum. Neurology 2004;62:994-7. PMID 15037710
- 55
- Szymanski AM, Saldana BD, Ferreira CR, et al. Mevalonic aciduria: does stem cell transplant fully cure disease? Pediatr Transplant 2020;24(1):e13604. PMID 31651069
- 56
- Tahara M, Sakai H, Nishikomori R, et al. Patient with neonatal-onset chronic hepatitis presenting with mevalonate kinase deficiency with a novel MVK gene mutation. Mod Rheumatol 2011;21(6):641-5. PMID 21399979
- 57
- ter Haar N, Jeyaratnam, J, Lachmann HJ, et al. The phenotype and genotype of mevalonate kinase deficiency. Arthritis Rheumatol 2016;68(11):2795-805.** PMID 27213830
- 58
- ter Haar N, Lachmann H, Özen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72(5):678-85. PMID 22753383
- 59
- Tsimaratos M, Kone-Paut I, Divry P, Philip N, Chabrol B. Mevalonic aciduria and hyper-IgD syndrome: two sides of the same coin. J Inherit Metab Dis 2001;24(3):413-4. PMID 11486910
- 60
- van der Burgh R, Nijhuis L, Pervolaraki K, et al. Defects in mitochondrial clearance predispose human monocytes to interleukin-1β hypersecretion. J Biol Chem 2014;289(8):5000-12. PMID 24356959
- 61
- van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol 2013;147(3):197-206.** PMID 23110805
- 62
- van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) 2008;87(6):301-10.** PMID 19011501
- 63
- Vuch J, Marcuzzi A, Bianco AM, Tommasini A, Zanin V, Crovella S. Evolutionary hypothesis of the mevalonate kinase deficiency. Med Hypotheses 2013;80(1):67-9. PMID 23168296
- 64
- Yogev Y, Shorer Z, Koifman A, et al. Limb girdle muscular disease caused by HMGCR mutation and statin myopathy treatable with mevalonolactone. Proc Nat Acad Sci USA 2023;120(7):e2217831120.** PMID 36745799
- 65
- Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol 2016;14(1):30.** PMID 27142780
- 66
- Zhang SQ, Jiang T, Li M, et al. Exome sequencing identifies MVK mutations in disseminated superficial actinic porokeratosis. Nat Genet 2012;44(10):1156–60. PMID 22983302
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Georg F Hoffmann MD
Dr. Hoffmann of the University Center for Child and Adolescent Medicine in Heidelberg has no relevant financial relationships to disclose.
See Profile
Editor
-
Deepa S Rajan MD
Dr. Rajan of UPMC Children's Hospital of Pittsburgh has no relevant financial relationships to disclose.
See Profile
Former Authors
- Dorothea Haas MD
- Jennifer Friedman MD
- K Michael Gibson PhD (original author)
Patient Profile
- Age range of presentation
-
- 0 month to 18 years
- Sex preponderance
-
- male=female
- Heredity
-
- heredity may be a factor
- heredity typical
- autosomal recessive
- Population groups selectively affected
-
- Northern Europeans
- Occupation groups selectively affected
-
- none selectively affected
ICD & OMIM codes
- ICD-9
-
- Disturbances of branched-chain amino-acid metabolism: 270.3
- ICD-10
-
- Other disorders of branched-chain amino-acid metabolism: E71.1
- OMIM
-
- Mevalonate kinase: #251170
- Hyperimmunoglobulinemia D syndrome: #260920
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neurogenetic Disorders
Pyruvate carboxylase deficiency
Nov. 09, 2024
-
Neurogenetic Disorders
Pelizaeus-Merzbacher disease
Oct. 31, 2024
-
Neurogenetic Disorders
Vanishing white matter disease
Oct. 30, 2024
-
Neurogenetic Disorders
Wilson disease
Oct. 23, 2024
-
Neurogenetic Disorders
Aromatic L-amino acid decarboxylase deficiency
Sep. 13, 2024
-
Stroke & Vascular Disorders
White matter abnormalities in the brain
Sep. 12, 2024
-
Neurogenetic Disorders
Hypermethioninemia
Sep. 12, 2024